Top ▲
GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
Unless otherwise stated all data on this page refer to the human proteins. Gene information is provided for human (Hs), mouse (Mm) and rat (Rn).
Show »« Hide
More detailed introduction
Neuropeptide Y (NPY) receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Neuropeptide Y Receptors [17]) are activated by the endogenous peptides neuropeptide Y (NPY, P01303), neuropeptide Y-(3-36), peptide YY (PYY, P10082), PYY-(3-36) and pancreatic polypeptide (PPY, P01298) (PP). The receptor originally identified as the Y3 receptor has been identified as the CXCR4 chemokine recepter (originally named LESTR, [15]). The y6 receptor is a functional gene product in mouse, absent in rat, but contains a frame-shift mutation in primates producing a truncated non-functional gene [12]. Three-dimensional structures have been determined for subtype active receptors Y1, Y2 and Y4 [14,24] and inactive antagonist bound Y1 and Y2 receptors [23,29]. Many of the agonists exhibit differing degrees of selectivity dependent on the species examined. For example, the potency of PP is greater at the rat Y4 receptor than at the human receptor [8]. In addition, many agonists lack selectivity for individual subtypes, but can exhibit comparable potency against pairs of NPY receptor subtypes, or have not been examined for activity at all subtypes. [125I]-PYY or [125I]-NPY can be used to label Y1, Y2, Y5 and y6 subtypes non-selectively, while [125I][cPP(1-7), NPY(19-23), Ala31, Aib32, Gln34]hPP may be used to label Y5 receptors preferentially (note that cPP denotes chicken peptide sequence and hPP is the human sequence).
|
Y1 receptor
C
Show summary »« Hide summary
More detailed page
|
||||||||||||||||||||||||||||||||||||
|
Y2 receptor
C
Show summary »« Hide summary
More detailed page
|
||||||||||||||||||||||||||||||||||||
|
Y4 receptor
C
Show summary »« Hide summary
More detailed page
|
||||||||||||||||||||||||||||||||||||
|
Y5 receptor
C
Show summary »« Hide summary
More detailed page
|
||||||||||||||||||||||||||||||||||||
|
y6 receptor
C
Show summary »« Hide summary
More detailed page
|
* Key recommended reading is highlighted with an asterisk
* Østergaard S, Jessen C, Paulsson JF, Kasimova MA, Conde-Frieboes KW, Straarup EM, Skyggebjerg RB, Ynddal L, Sanfridson A, Wulff BS et al.. (2025) Variant screening of PYY3-36 leads to potent long-acting PYY analogs with superior Y2 receptor selectivity. Sci Transl Med, 17 (791): eadq6392. [PMID:40138456]
* Bowers ME, Choi DC, Ressler KJ. (2012) Neuropeptide regulation of fear and anxiety: Implications of cholecystokinin, endogenous opioids, and neuropeptide Y. Physiol Behav, 107 (5): 699-710. [PMID:22429904]
Decressac M, Barker RA. (2012) Neuropeptide Y and its role in CNS disease and repair. Exp Neurol, 238 (2): 265-72. [PMID:23022456]
Holzer P, Reichmann F, Farzi A. (2012) Neuropeptide Y, peptide YY and pancreatic polypeptide in the gut-brain axis. Neuropeptides, 46 (6): 261-74. [PMID:22979996]
* Michel MC, Beck-Sickinger A, Cox H, Doods HN, Herzog H, Larhammar D, Quirion R, Schwartz T, Westfall T. (1998) XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol Rev, 50 (1): 143-50. [PMID:9549761]
Morales-Medina JC, Dumont Y, Quirion R. (2010) A possible role of neuropeptide Y in depression and stress. Brain Res, 1314: 194-205. [PMID:19782662]
* Pedragosa-Badia X, Stichel J, Beck-Sickinger AG. (2013) Neuropeptide Y receptors: how to get subtype selectivity. Front Endocrinol (Lausanne), 4: 5. [PMID:23382728]
* Shebanits K, Andersson-Assarsson JC, Larsson I, Carlsson LMS, Feuk L, Larhammar D. (2018) Copy number of pancreatic polypeptide receptor gene NPY4R correlates with body mass index and waist circumference. PLoS One, 13 (4): e0194668. [PMID:29621259]
* Shebanits K, Vasile S, Xu B, Gutiérrez-de-Terán H, Larhammar D. (2019) Functional characterization in vitro of twelve naturally occurring variants of the human pancreatic polypeptide receptor NPY4R. Neuropeptides, 76: 101933. [PMID:31230758]
Zengin A, Zhang L, Herzog H, Baldock PA, Sainsbury A. (2010) Neuropeptide Y and sex hormone interactions in humoral and neuronal regulation of bone and fat. Trends Endocrinol Metab, 21 (7): 411-8. [PMID:20202858]
* Zhang L, Bijker MS, Herzog H. (2011) The neuropeptide Y system: pathophysiological and therapeutic implications in obesity and cancer. Pharmacol Ther, 131 (1): 91-113. [PMID:21439311]
1. Bard JA, Walker MW, Branchek TA, Weinshank RL. (1995) Cloning and functional expression of a human Y4 subtype receptor for pancreatic polypeptide, neuropeptide Y, and peptide YY. J Biol Chem, 270 (45): 26762-5. [PMID:7592911]
2. Bonaventure P, Nepomuceno D, Mazur C, Lord B, Rudolph DA, Jablonowski JA, Carruthers NI, Lovenberg TW. (2004) Characterization of N-(1-Acetyl-2,3-dihydro-1H-indol-6-yl)-3-(3-cyano-phenyl)-N-[1-(2-cyclopentyl-ethyl)-piperidin-4yl]acrylamide (JNJ-5207787), a small molecule antagonist of the neuropeptide Y Y2 receptor. J Pharmacol Exp Ther, 308 (3): 1130-7. [PMID:14617685]
3. Cabrele C, Wieland HA, Koglin N, Stidsen C, Beck-Sickinger AG. (2002) Ala31-Aib32: identification of the key motif for high affinity and selectivity of neuropeptide Y at the Y5-receptor. Biochemistry, 41 (25): 8043-9. [PMID:12069595]
4. Cox HM, Tough IR. (1995) Functional characterization of receptors with affinity for PYY, NPY, [Leu31,Pro34]NPY and PP in a human colonic epithelial cell line. Br J Pharmacol, 116 (6): 2673-8. [PMID:8590988]
5. Doods H, Gaida W, Wieland HA, Dollinger H, Schnorrenberg G, Esser F, Engel W, Eberlein W, Rudolf K. (1999) BIIE0246: a selective and high affinity neuropeptide Y Y(2) receptor antagonist. Eur J Pharmacol, 384 (2-3): R3-5. [PMID:10611450]
6. Doods HN, Wienen W, Entzeroth M, Rudolf K, Eberlein W, Engel W, Wieland HA. (1995) Pharmacological characterization of the selective nonpeptide neuropeptide Y Y1 receptor antagonist BIBP 3226. J Pharmacol Exp Ther, 275 (1): 136-42. [PMID:7562541]
7. Dumont Y, Thakur M, Beck-Sickinger A, Fournier A, Quirion R. (2004) Characterization of a new neuropeptide Y Y5 agonist radioligand: [125I][cPP(1-7), NPY(19-23), Ala31, Aib32, Gln34]hPP. Neuropeptides, 38 (4): 163-74. [PMID:15337369]
8. Eriksson H, Berglund MM, Holmberg SK, Kahl U, Gehlert DR, Larhammar D. (1998) The cloned guinea pig pancreatic polypeptide receptor Y4 resembles more the human Y4 than does the rat Y4. Regul Pept, 75-76: 29-37. [PMID:9802391]
9. Gehlert DR, Beavers LS, Johnson D, Gackenheimer SL, Schober DA, Gadski RA. (1996) Expression cloning of a human brain neuropeptide Y Y2 receptor. Mol Pharmacol, 49 (2): 224-8. [PMID:8632753]
10. Gerald C, Walker MW, Criscione L, Gustafson EL, Batzl-Hartmann C, Smith KE, Vaysse P, Durkin MM, Laz TM, Linemeyer DL et al.. (1996) A receptor subtype involved in neuropeptide-Y-induced food intake. Nature, 382 (6587): 168-71. [PMID:8700207]
11. Gerald C, Walker MW, Vaysse PJ, He C, Branchek TA, Weinshank RL. (1995) Expression cloning and pharmacological characterization of a human hippocampal neuropeptide Y/peptide YY Y2 receptor subtype. J Biol Chem, 270 (45): 26758-61. [PMID:7592910]
12. Gregor P, Millham ML, Feng Y, DeCarr LB, McCaleb ML, Cornfield LJ. (1996) Cloning and characterization of a novel receptor to pancreatic polypeptide, a member of the neuropeptide Y receptor family. FEBS Lett, 381: 58-62. [PMID:8641440]
13. Kanatani A, Ishihara A, Iwaasa H, Nakamura K, Okamoto O, Hidaka M, Ito J, Fukuroda T, MacNeil DJ, Van der Ploeg LH et al.. (2000) L-152,804: orally active and selective neuropeptide Y Y5 receptor antagonist. Biochem Biophys Res Commun, 272 (1): 169-73. [PMID:10872822]
14. Kang H, Park C, Choi YK, Bae J, Kwon S, Kim J, Choi C, Seok C, Im W, Choi HJ. (2023) Structural basis for Y2 receptor-mediated neuropeptide Y and peptide YY signaling. Structure, 31 (1): 44-57.e6. [PMID:36525977]
15. Loetscher M, Geiser T, O'Reilly T, Zwahlen R, Baggiolini M, Moser B. (1994) Cloning of a human seven-transmembrane domain receptor, LESTR, that is highly expressed in leukocytes. J Biol Chem, 269 (1): 232-7. [PMID:8276799]
16. Lundell I, Blomqvist AG, Berglund MM, Schober DA, Johnson D, Statnick MA, Gadski RA, Gehlert DR, Larhammar D. (1995) Cloning of a human receptor of the NPY receptor family with high affinity for pancreatic polypeptide and peptide YY. J Biol Chem, 270 (49): 29123-8. [PMID:7493937]
17. Michel MC, Beck-Sickinger A, Cox H, Doods HN, Herzog H, Larhammar D, Quirion R, Schwartz T, Westfall T. (1998) XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol Rev, 50 (1): 143-50. [PMID:9549761]
18. Petitto JM, Huang Z, McCarthy DB. (1994) Molecular cloning of NPY-Y1 receptor cDNA from rat splenic lymphocytes: evidence of low levels of mRNA expression and [125I]NPY binding sites. J Neuroimmunol, 54 (1-2): 81-6. [PMID:7929806]
19. Schüß C, Vu O, Mishra NM, Tough IR, Du Y, Stichel J, Cox HM, Weaver CD, Meiler J, Emmitte KA et al.. (2023) Structure-Activity Relationship Study of the High-Affinity Neuropeptide Y4 Receptor Positive Allosteric Modulator VU0506013. J Med Chem, 66 (13): 8745-8766. [PMID:37339079]
20. Schüß C, Vu O, Schubert M, Du Y, Mishra NM, Tough IR, Stichel J, Weaver CD, Emmitte KA, Cox HM et al.. (2021) Highly Selective Y4 Receptor Antagonist Binds in an Allosteric Binding Pocket. J Med Chem, 64 (5): 2801-2814. [PMID:33595306]
21. Shebanits K, Andersson-Assarsson JC, Larsson I, Carlsson LMS, Feuk L, Larhammar D. (2018) Copy number of pancreatic polypeptide receptor gene NPY4R correlates with body mass index and waist circumference. PLoS One, 13 (4): e0194668. [PMID:29621259]
22. Shebanits K, Vasile S, Xu B, Gutiérrez-de-Terán H, Larhammar D. (2019) Functional characterization in vitro of twelve naturally occurring variants of the human pancreatic polypeptide receptor NPY4R. Neuropeptides, 76: 101933. [PMID:31230758]
23. Tang T, Hartig C, Chen Q, Zhao W, Kaiser A, Zhang X, Zhang H, Qu H, Yi C, Ma L et al.. (2021) Structural basis for ligand recognition of the neuropeptide Y Y2 receptor. Nat Commun, 12 (1): 737. [PMID:33531491]
24. Tang T, Tan Q, Han S, Diemar A, Löbner K, Wang H, Schüß C, Behr V, Mörl K, Wang M et al.. (2022) Receptor-specific recognition of NPY peptides revealed by structures of NPY receptors. Sci Adv, 8 (18): eabm1232. [PMID:35507650]
25. Tough IR, Holliday ND, Cox HM. (2006) Y(4) receptors mediate the inhibitory responses of pancreatic polypeptide in human and mouse colon mucosa. J Pharmacol Exp Ther, 319 (1): 20-30. [PMID:16807358]
26. Wieland HA, Engel W, Eberlein W, Rudolf K, Doods HN. (1998) Subtype selectivity of the novel nonpeptide neuropeptide Y Y1 receptor antagonist BIBO 3304 and its effect on feeding in rodents. Br J Pharmacol, 125: 549-555. [PMID:9806339]
27. Wieland HA, Willim KD, Entzeroth M, Wienen W, Rudolf K, Eberlein W, Engel W, Doods HN. (1995) Subtype selectivity and antagonistic profile of the nonpeptide Y1 receptor antagonist BIBP 3226. J Pharmacol Exp Ther, 275 (1): 143-9. [PMID:7562543]
28. Yan H, Yang J, Marasco J, Yamaguchi K, Brenner S, Collins F, Karbon W. (1996) Cloning and functional expression of cDNAs encoding human and rat pancreatic polypeptide receptors. Proc Natl Acad Sci USA, 93 (10): 4661-5. [PMID:8643460]
29. Yang Z, Han S, Keller M, Kaiser A, Bender BJ, Bosse M, Burkert K, Kögler LM, Wifling D, Bernhardt G et al.. (2018) Structural basis of ligand binding modes at the neuropeptide Y Y1 receptor. Nature, 556 (7702): 520-524. [PMID:29670288]
Subcommittee members:
Dan Larhammar (Chairperson)
Annette G. Beck-Sickinger
William F. Colmers
Helen M. Cox
Herbert Herzog
Remi Quirion
Thue Schwartz
Thomas Westfall |
Database page citation (select format):
Concise Guide to PHARMACOLOGY citation:
Alexander SPH, Christopoulos A, Davenport AP, Kelly E, Mathie AA, Peters JA, Veale EL, Armstrong JF, Faccenda E, Harding SD, Davies JA et al. (2023) The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors. Br J Pharmacol. 180 Suppl 2:S23-S144.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License

The Y1 agonists indicated are selective relative to Y2 receptors. BIBP3226 is selective relative to Y2, Y4 and Y5 receptors [10]. NPY-(13-36) is Y2 selective relative to Y1 and Y5 receptors. PYY-(3-36) is Y2 selective relative to Y1 receptors, and new long-acting analogues of PYY(3-36) exhibit improved Y2 selectivity. Note that Pro34-containing NPY and PYY can also bind Y4 and Y5, thus they are selective only relative to Y2. The y6 receptor is a pseudogene in humans, but is functional in mouse, rabbit and some other mammals. Human Y4 has several naturally occurring sequence variants [22] and the human NPY4R gene displays extensive gene copy number variation [21].